SILK - רווח נקי למניה (EPS TTM) Silk Road Medical Inc.

Silk Road Medical, Inc (SILK) has developed an innovative carotid artery therapy for stroke prevention that has become a surgical benchmark. The 12-month net income per share snapshot demonstrates a mathematical profitability trajectory, where the -1.45 mark records this metric. Profit growth is driven by the high value of TCAR devices, while the acquisition by the Medtronic behemoth confirms technological dominance and eliminates development risks.
SILK (Silk Road Medical Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Stable demand for Silk Road Medical, Inc (SILK) biopharmaceuticals faces risks of supply chain disruptions and regulatory barriers. These operational complexities directly impact the final earnings per share. This metric measures the real cash efficiency of the business, adjusted for the total volume of shares outstanding. Sharp deviations in this indicator signal fundamental instability or a decline in profitability. By analyzing the 12-month rolling EPS, an investor determines the predictability of the company's earnings.